Paul Quinlan, an officer of Oruka Therapeutics Inc, filed a Form 144 notice on November 20, 2026, disclosing a proposed sale of 24,000 shares of common stock to be acquired through the exercise of stock options.
Key Highlights
- Proposed sale size: 24,000 shares of Oruka Therapeutics Inc common stock, with an aggregate market value of $2,341,680.00.
- Acquisition method: Securities are to be received upon the exercise of stock options, with an acquisition date and payment date both listed as November 20, 2026.
- Approximate sale date: November 20, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
- Shares outstanding: 67,822,359 shares of common stock were listed as outstanding at the time of the notice.
- 10b5-1 plan: The notice indicates a Rule 10b5-1 trading plan adopted on May 15, 2026.
- Prior sales in past three months: Quinlan sold 9,000 shares on October 20, 2026 (gross proceeds $706,734.90), 10,000 shares on September 21, 2026 (gross proceeds $936,418.00), and 1,039 shares on September 15, 2026 (gross proceeds $99,442.69).
Oruka Therapeutics Officer Paul Quinlan Proposes Option-Backed Share Sale on NASDAQ
According to the filing, Paul Quinlan, identified as an officer of Oruka Therapeutics Inc (NASDAQ:ORKA), submitted a Form 144 notice dated November 20, 2026, to the U.S. Securities and Exchange Commission. The notice covers a proposed sale of 24,000 shares of common stock, with the securities to be acquired via the exercise of stock options granted by the issuer. The aggregate market value of the proposed sale is listed as $2,341,680.00. The broker named for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
The filing states that the securities "were and will be received upon the exercise of stock options over the next three months" and that "the dates of acquisition and payment were and will be the dates of exercise/sale." Quinlan's notice also references a Rule 10b5-1 trading plan with an adoption date of May 15, 2026. The total shares of common stock outstanding are reported as 67,822,359.
The filing discloses three prior sales of Oruka Therapeutics common stock by Quinlan in the preceding three months. On September 15, 2026, 1,039 shares were sold for gross proceeds of $99,442.69. On September 21, 2026, 10,000 shares were sold for gross proceeds of $936,418.00, and on October 20, 2026, 9,000 shares were sold for gross proceeds of $706,734.90. All prior sales are listed as 10b5-1 plan transactions.
What Was Disclosed
Paul Quinlan, an officer of Oruka Therapeutics Inc, filed a Form 144 notice disclosing a proposed sale of 24,000 shares to be obtained via stock option exercise, with an aggregate market value of $2,341,680.00, under a Rule 10b5-1 plan adopted May 15, 2026.





Please wait processing your request...